Medtronic Evolut™ TAVR platform outperforms surgery w

Medtronic Evolut™ TAVR platform outperforms surgery with sustained valve performance for low-risk patients at four years

TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk TrialDUBLIN and S...

Related Keywords

Ireland , Dublin , Michael Reardon , Prnewswire Medtronic , Rachel Murray , Ryan Weispfenning , Medtronic Evolut , Cardiovascular Research Foundation , Our Mission , Linkedin , Cardiovascular Research , Exchange Commission , Journal Of The American College Cardiology , Medtronic , Evolut Low Risk , Only Evolut , Transcatheter Cardiovascular Therapeutics , American College , Allison Family Distinguished Chair , Houston Methodist Hospital , Low Risk Trial ,